# FDXR

## Overview
The FDXR gene encodes the protein ferredoxin reductase, a mitochondrial flavoprotein that plays a pivotal role in electron transfer processes within the cell. As a key component of the mitochondrial electron transport chain, ferredoxin reductase facilitates the transfer of electrons from NADPH to ferredoxin proteins, such as FDX1 and FDX2, which are essential for the biogenesis of iron-sulfur clusters and steroidogenesis (Slone2020Integrated; Zhang2017Ferredoxin). This protein is integral to maintaining mitochondrial function and cellular metabolism, as it also contributes to iron homeostasis and lipid regulation through its interactions with the p53 tumor suppressor pathway (Zhang2017Ferredoxin; Zhang2022Ferredoxin). Mutations in the FDXR gene have been associated with a range of mitochondrial disorders, underscoring its clinical significance in human health (Peng2017Biallelic).

## Structure
The FDXR (ferredoxin reductase) protein is a mitochondrial flavoprotein involved in electron transfer processes. Its primary structure consists of a sequence of amino acids that form a compact, globular shape. The secondary structure of FDXR includes alpha helices and beta sheets, which contribute to its stability and function. The tertiary structure of FDXR is characterized by a FAD-binding domain, which is crucial for its role in electron transfer from NADPH to ferredoxin proteins, such as FDX1 and FDX2 (Slone2020Integrated; Zhang2017Ferredoxin).

In terms of quaternary structure, FDXR may interact with ferredoxin proteins to facilitate electron transfer, although specific details on these interactions are not provided in the context. Common post-translational modifications of FDXR include phosphorylation, which can affect its activity and interactions with other proteins (Zhang2017Ferredoxin).

The FDXR protein plays a critical role in the biogenesis of iron-sulfur clusters and steroidogenesis, highlighting its importance in maintaining mitochondrial function and cellular metabolism (Zhang2017Ferredoxin; Gervason2019Physiologically).

## Function
The FDXR gene encodes ferredoxin reductase, a mitochondrial flavoprotein that plays a critical role in electron transfer processes. In healthy human cells, FDXR is involved in transferring electrons from NADPH to ferredoxin proteins, FDX1 and FDX2, which are essential for various mitochondrial functions (Slone2020Integrated; Zhang2017Ferredoxin). This electron transfer is crucial for the biogenesis of iron-sulfur (Fe-S) clusters, which are vital cofactors for numerous cellular processes, including the electron transport chain (ETC) and steroidogenesis (Slone2020Integrated; Zhang2022Ferredoxin).

FDXR is also involved in maintaining mitochondrial iron homeostasis, preventing iron overload that can lead to cellular dysfunction and oxidative stress (Slone2020Integrated). It regulates the expression of iron regulatory proteins and is necessary for the proper functioning of the p53 tumor suppressor pathway, which is involved in apoptosis and tumor suppression (Zhang2017Ferredoxin). The FDXR-p53 regulatory loop is essential for maintaining iron balance and preventing iron-related pathologies (Zhang2017Ferredoxin).

In addition to its role in iron metabolism, FDXR is implicated in lipid homeostasis through its interaction with p53, influencing the expression of cholesterol and triglyceride regulatory proteins (Zhang2022Ferredoxin).

## Clinical Significance
Mutations in the FDXR gene are linked to a novel mitochondriopathy characterized by optic atrophy, neurodegeneration, and peripheral neuropathy. These mutations often affect the FAD/NAD(P)-binding domain, leading to protein instability and loss of function. A notable mutation, p.R392W, is a hotspot associated with severe outcomes, including early death in homozygous individuals (Peng2017Biallelic). FDXR mutations result in reduced electron transport chain function and increased reactive oxygen species production, contributing to mitochondrial iron overload and membrane depolarization (Slone2020Integrated). 

Clinical manifestations of FDXR mutations include optic atrophy, hearing impairment, developmental delays, and in severe cases, conditions like Leigh syndrome. These mutations can lead to decreased enzyme activity, reduced ATP production, and impaired mitochondrial complex activities, particularly affecting complexes II and III (Peng2017Biallelic; Stenton2021Expanding). 

Mouse models with FDXR mutations exhibit similar mitochondrial dysfunction and visual acuity defects, including retinal ganglion cell loss and optic nerve abnormalities (Peng2017Biallelic). The clinical spectrum of FDXR deficiency is broad, with some patients experiencing spasticity, respiratory failure, and early death (Peng2017Biallelic).

## Interactions
FDXR (ferredoxin reductase) is involved in several protein interactions that are crucial for its function in cellular processes. One significant interaction is with MPZL3, a mitochondrial protein that plays a role in epidermal differentiation. MPZL3 binds to FDXR, enhancing its enzymatic activity, which is essential for the regulation of reactive oxygen species (ROS) and the promotion of epidermal differentiation. This interaction is validated through proximity ligation analysis and co-immunoprecipitation, indicating a functional partnership between the two proteins (Bhaduri2015Network).

FDXR also interacts with the p53 tumor suppressor pathway. It is a target of p53 and is involved in modulating p53-dependent apoptosis. FDXR's role in iron homeostasis is linked to its interaction with iron regulatory protein 2 (IRP2), which affects p53 expression. FDXR deficiency leads to increased IRP2 expression, which in turn suppresses p53 expression by inhibiting its mRNA translation (Zhang2017Ferredoxin).

These interactions highlight FDXR's involvement in critical cellular pathways, including ROS regulation, epidermal differentiation, and iron metabolism, through its interactions with MPZL3 and components of the p53 pathway.


## References


[1. (Slone2020Integrated) Jesse D. Slone, Li Yang, Yanyan Peng, Luis F. Queme, Belinda Harris, Stacey J. Sukoff Rizzo, Torrian Green, Jennifer L. Ryan, Michael P. Jankowski, Laura G. Reinholdt, and Taosheng Huang. Integrated analysis of the molecular pathogenesis of fdxr-associated disease. Cell Death &amp; Disease, June 2020. URL: http://dx.doi.org/10.1038/s41419-020-2637-3, doi:10.1038/s41419-020-2637-3. This article has 21 citations.](https://doi.org/10.1038/s41419-020-2637-3)

[2. (Peng2017Biallelic) Yanyan Peng, Deepali N Shinde, C Alexander Valencia, Jun-Song Mo, Jill Rosenfeld, Megan Truitt Cho, Adam Chamberlin, Zhuo Li, Jie Liu, Baoheng Gui, Rachel Brockhage, Alice Basinger, Brenda Alvarez-Leon, Peter Heydemann, Pilar L Magoulas, Andrea M Lewis, Fernando Scaglia, Solange Gril, Shuk Ching Chong, Matthew Bower, Kristin G Monaghan, Rebecca Willaert, Maria-Renee Plona, Rich Dineen, Francisca Milan, George Hoganson, Zoe Powis, Katherine L Helbig, Jennifer Keller-Ramey, Belinda Harris, Laura C Anderson, Torrian Green, Stacey J Sukoff Rizzo, Julie Kaylor, Jiani Chen, Min-Xin Guan, Elizabeth Sellars, Steven P Sparagana, James B Gibson, Laura G Reinholdt, Sha Tang, and Taosheng Huang. Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Human Molecular Genetics, 26(24):4937–4950, October 2017. URL: http://dx.doi.org/10.1093/hmg/ddx377, doi:10.1093/hmg/ddx377. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddx377)

[3. (Gervason2019Physiologically) Sylvain Gervason, Djabir Larkem, Amir Ben Mansour, Thomas Botzanowski, Christina S. Müller, Ludovic Pecqueur, Gwenaelle Le Pavec, Agnès Delaunay-Moisan, Omar Brun, Jordi Agramunt, Anna Grandas, Marc Fontecave, Volker Schünemann, Sarah Cianférani, Christina Sizun, Michel B. Tolédano, and Benoit D’Autréaux. Physiologically relevant reconstitution of iron-sulfur cluster biosynthesis uncovers persulfide-processing functions of ferredoxin-2 and frataxin. Nature Communications, August 2019. URL: http://dx.doi.org/10.1038/s41467-019-11470-9, doi:10.1038/s41467-019-11470-9. This article has 119 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-11470-9)

[4. (Stenton2021Expanding) Sarah L. Stenton, Dorota Piekutowska‐Abramczuk, Lea Kulterer, Robert Kopajtich, Kristl G. Claeys, Elżbieta Ciara, Johannes Eisen, Rafał Płoski, Ewa Pronicka, Katarzyna Malczyk, Matias Wagner, Saskia B. Wortmann, and Holger Prokisch. Expanding the clinical and genetic spectrum of fdxr deficiency by functional validation of variants of uncertain significance. Human Mutation, 42(3):310–319, January 2021. URL: http://dx.doi.org/10.1002/humu.24160, doi:10.1002/humu.24160. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.24160)

[5. (Zhang2017Ferredoxin) Yanhong Zhang, Yingjuan Qian, Jin Zhang, Wensheng Yan, Yong-Sam Jung, Mingyi Chen, Eric Huang, Kent Lloyd, Yuyou Duan, Jian Wang, Gang Liu, and Xinbin Chen. Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2. Genes &amp; Development, 31(12):1243–1256, June 2017. URL: http://dx.doi.org/10.1101/gad.299388.117, doi:10.1101/gad.299388.117. This article has 103 citations.](https://doi.org/10.1101/gad.299388.117)

[6. (Bhaduri2015Network) Aparna Bhaduri, Alexander Ungewickell, Lisa D. Boxer, Vanessa Lopez-Pajares, Brian J. Zarnegar, and Paul A. Khavari. Network analysis identifies mitochondrial regulation of epidermal differentiation by mpzl3 and fdxr. Developmental Cell, 35(4):444–457, November 2015. URL: http://dx.doi.org/10.1016/j.devcel.2015.10.023, doi:10.1016/j.devcel.2015.10.023. This article has 44 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.devcel.2015.10.023)

[7. (Zhang2022Ferredoxin) Yanhong Zhang, Shakur Mohibi, Demitria M. Vasilatis, Mingyi Chen, Jin Zhang, and Xinbin Chen. Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the abca1–srebp pathway. Oncogene, 41(12):1718–1726, February 2022. URL: http://dx.doi.org/10.1038/s41388-021-02100-0, doi:10.1038/s41388-021-02100-0. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-021-02100-0)